European journal of cancer
Journal
Overview
publication venue for
-
Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma.
1991
-
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium..
202.
2024
-
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients..
199.
2024
-
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects..
199.
2023
-
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations..
196.
2023
-
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study..
192.
2023
-
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
2023
-
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy..
177.
2022
-
The regulation of CD73 in non-small cell lung cancer..
170.
2022
-
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302..
170.
2022
-
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment..
168.
2022
-
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma..
163.
2022
-
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region..
159.
2021
-
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006..
157.
2021
-
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts..
156.
2021
-
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice..
157.
2021
-
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour..
155.
2021
-
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer..
150.
2021
-
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy..
149.
2021
-
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study..
146.
2021
-
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma..
144.
2020
-
Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways..
144.
2020
-
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools..
143.
2020
-
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma..
138.
2020
-
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma..
135.
2020
-
Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..
133.
2020
-
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative..
130.
2020
-
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma..
126.
2020
-
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials..
125.
2020
-
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial..
125.
2019
-
Clinical features of neuroendocrine prostate cancer..
121.
2019
-
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours..
120.
2019
-
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial..
119.
2019
-
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial..
114.
2019
-
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors..
114.
2019
-
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort..
109.
2019
-
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study..
109.
2019
-
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer..
108.
2019
-
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA..
106.
2018
-
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3..
104.
2018
-
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer..
101.
2018
-
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity..
99.
2018
-
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT..
96.
2018
-
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update..
94.
2018
-
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study..
94.
2018
-
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma..
89.
2017
-
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma..
86.
2017
-
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma..
86.
2017
-
Menopausal hormone therapy and cancer risk: An overestimated risk?.
84.
2017
-
Health-related quality of life results from the phase III CheckMate 067 study..
82.
2017
-
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study..
80.
2017
-
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours..
76.
2017
-
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients..
73.
2017
-
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab..
64.
2016
-
Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis..
63.
2016
-
RECIST 1.1-Update and clarification: From the RECIST committee..
62.
2016
-
Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours..
59.
2016
-
Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study..
51.
2015
-
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas..
51.
2015
-
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer..
51.
2015
-
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies..
51.
2015
-
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer..
51.
2015
-
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression..
51.
2015
-
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma..
50.
2014
-
Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies..
50.
2014
-
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma..
50.
2014
-
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events..
50.
2014
-
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma..
50.
2014
-
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials..
50.
2013
-
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report..
49.
2013
-
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort..
49.
2013
-
Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy..
49.
2013
-
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies..
49.
2013
-
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update..
49.
2013
-
Assessment of the Memorial Sloan-Kettering Cancer Center nomogram to predict sentinel lymph node metastases in a Dutch breast cancer population..
49.
2012
-
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer..
49.
2012
-
Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours..
48.
2012
-
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality..
48.
2012
-
Long term renal toxicity of ifosfamide in adult patients--5 year data..
48.
2012
-
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology..
48.
2012
-
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial..
48.
2012
-
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study..
48.
2011
-
Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy..
48.
2011
-
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy..
48.
2011
-
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype..
47.
2011
-
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology..
47.
2010
-
High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma..
47.
2010
-
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib..
46.
2010
-
Amplification of epidermal growth factor receptor gene in renal cell carcinoma..
46.
2010
-
Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study..
46.
2010
-
The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation..
46.
2010
-
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours..
46.
2010
-
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies..
46.
2009
-
Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients..
45.
2009
-
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion..
45.
2009
-
Management and outcome of stage 3 neuroblastoma..
45.
2008
-
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer..
44.
2008
-
Management of malignant bowel obstruction..
44.
2008
-
Prostate volume and adverse prostate cancer features: fact not artifact..
43.
2007
-
UbcH10 is overexpressed in malignant breast carcinomas..
43.
2007
-
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)..
44.
2007
-
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)..
44.
2007
-
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)..
43.
2006
-
Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy..
42.
2006
-
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984)..
42.
2006
-
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours..
42.
2005
-
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial..
41.
2005
-
Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck..
41.
2005
-
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose..
40.
2004
-
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group..
40.
2004
-
Studies with cytotoxic agents suggest that apoptosis is not a major determinant of clonogenic death in neuroblastoma cells..
39.
2003
-
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965)..
39.
2003
-
Does use of alternative medicine predict survival from cancer?.
39.
2003
-
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)..
39.
2003
-
Phase II trial of ZD0473 as second-line therapy in mesothelioma..
38 Suppl 8.
2002
-
Tamoxifen for primary breast cancer prevention in BRCA heterozygotes..
38 Suppl 6.
2002
-
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer..
38.
2002
-
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma..
38.
2002
-
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours..
36.
2000
-
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs..
36.
2000
-
Prevalence of complementary therapy use by women with breast cancer. A population-based survey..
36.
2000
-
Radiotherapy of the brain in elderly patients. arbiter:.
36.
2000
-
Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice..
36.
2000
-
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines..
35.
1999
-
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast..
33.
1997
-
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group..
33.
1997
-
Phase II study of semisynthetic paclitaxel in metastatic breast cancer..
33.
1997
-
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group..
33.
1997
-
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma..
33.
1997
-
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial..
32A.
1996
-
Effects of suramin on human lung cancer cell lines..
31A.
1995
-
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group..
31A Suppl 4.
1995
-
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma..
30A.
1994
-
In vitro sequence-dependent synergistic effect of suramin and camptothecin..
30A.
1994
-
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress..
30A.
1994
-
Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures..
29A.
1993
-
Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS)..
29A Suppl 1.
1993
-
Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group..
28.
1992
-
Effects of extracellular matrix on the response of endothelial cells to radiation in vitro..
28A.
1992
-
Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group..
28A.
1992
-
Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients..
27.
1991
-
Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer..
27.
1991
-
Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines..
27.
1991
-
Haemodynamic effects of recombinant interleukin-2 administered by constant infusion..
27.
1991
-
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group..
27.
1991
-
Multimodality treatment of malignant germ cell tumours of the mediastinum..
27.
1991
-
Pilot study of teniposide in combination chemotherapy for small cell lung cancer..
27.
1991
-
Antiproliferative effects of suramin on androgen responsive tumour cells..
26.
1990
-
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology..
112.
2019
-
Comment on: Does use of alternative medicine predict survival from cancer? Eur J Cancer 2003, 39, 372-377..
39.
2003
-
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract..
36 Suppl 2.
2000
-
Unusual clonal evolution during blast crisis of chronic myeloid leukaemia (CML).
30A.
1994
-
Magnetic resonance imaging in breast cancer: is seeing always believing?.
41.
2005
-
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.
2020
-
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
2017
-
Are we ready to predict late effects? A systematic review of clinically useful prediction models.
2015
-
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
2014
-
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis.
2021
-
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
2021
-
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
2016
-
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT).
2014
-
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
2011
-
Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
2021
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)